Skip to content
value.today

Rivus Pharmaceuticals, Inc.

🇺🇸 Charlottesville, Virginia, USAPharmaceuticalsFounded 2019
Total raised
$223 M
4 rounds on record
Latest round
$57 M
Jan 2025
First round on record
Mar 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rivus Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2025$57 MNo. 4$50 to $250 million

Rivus Pharmaceuticals, Inc.: Raise no. 4, Jan 2025

Investors in this round

7 investors had bought by the notice of Jan 16, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$57 M of $57 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allen Cunningham · Executive Officer, Director
  • Jayson Dallas · Executive Officer, Director
  • Robert Schott · Executive Officer
  • Shaharyar Khan · Executive Officer, Director
  • Tom O'Neil · Executive Officer
  • Derek DiRocco · Director
  • Erin Lavelle · Director
  • Francesco De Rubertis · Director
  • Ian Smith · Director
  • Rick Winningham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allen Cunningham, Chief Operating Officer. Source: SEC Form D, newest notice filed Jan 16, 2025. Read the notice at the SEC.

equitySEC
Aug 2024$66 MNo. 3$50 to $250 million

Rivus Pharmaceuticals, Inc.: Raise no. 3, Aug 2024

Investors in this round

7 investors had bought by the notice of Sep 17, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$66 M of $66 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allen Cunningham · Executive Officer, Director
  • Jayson Dallas · Executive Officer, Director
  • Nancy Hargreaves · Executive Officer
  • Shaharyar Khan · Executive Officer, Director
  • Derek DiRocco · Director
  • Francesco De Rubertis · Director
  • Ian Smith · Director
  • Rick Winningham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allen Cunningham, Chief Operating Officer. Source: SEC Form D, newest notice filed Sep 17, 2024. Read the notice at the SEC.

equitySEC
Aug 2022$66 MNo. 2$50 to $250 million

Rivus Pharmaceuticals, Inc.: Raise no. 2, Aug 2022

Investors in this round

7 investors had bought by the notice of Sep 17, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$66 M of $66 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allen Cunningham · Executive Officer, Director
  • Jayson Dallas · Executive Officer, Director
  • Nancy Hargreaves · Executive Officer
  • Shaharyar Khan · Executive Officer, Director
  • Derek DiRocco · Director
  • Francesco De Rubertis · Director
  • Ian Smith · Director
  • Rick Winningham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allen Cunningham, Chief Operating Officer. Source: SEC Form D, newest notice filed Sep 17, 2024. Read the notice at the SEC.

equitySEC
Mar 2019$35 MNo. 1$10 to $50 million

Rivus Pharmaceuticals, Inc.: Raise no. 1, Mar 2019

Investors in this round

4 investors had bought by the notice of Oct 4, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Conversion of other rights to acquire shares of stock and the offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allen Cunningham · Executive Officer, Director
  • Shaharyar Khan · Executive Officer, Director
  • Francesco De Rubertis · Director
  • Jayson Dallas · Director
  • Patrick Enright · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Allen Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 4, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Rivus Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2025

That is all the official record says: Rivus Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Rivus Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rivus Pharmaceuticals, Inc.
NameRoleNamed in
Allen CunninghamExecutive officerJan 2025
Jayson DallasExecutive officerJan 2025
Robert SchottExecutive officerJan 2025
Shaharyar KhanExecutive officerJan 2025
Tom O'NeilExecutive officerJan 2025
Nancy HargreavesExecutive officerSep 2024
Allen CunninghamDirectorJan 2025
Derek DiRoccoDirectorJan 2025
Erin LavelleDirectorJan 2025
Francesco De RubertisDirectorJan 2025
Ian SmithDirectorJan 2025
Jayson DallasDirectorJan 2025
Rick WinninghamDirectorJan 2025
Shaharyar KhanDirectorJan 2025
Patrick EnrightDirectorOct 2021